WHO Sets New Standards for Long-Acting Injectable TB Treatments

The World Health Organization (WHO) has announced the release of target regimen profiles aimed at guiding the development of long-acting injectable (LAI) treatments for tuberculosis (TB). This initiative seeks to alleviate the burden of daily oral medication, making TB care more accessible and manageable for patients.

Traditionally, TB treatment requires patients to adhere to a regimen of oral medications over several months, which can be difficult for both patients and healthcare systems. The introduction of long-acting injectables is intended to provide a viable alternative, significantly reducing the frequency of medication administration and improving adherence.

The newly established target regimen profiles outline the essential characteristics that future injectable treatments should possess to be considered effective, safe, and practical. These profiles serve as a guideline for pharmaceutical companies, researchers, and organizations involved in TB care, setting minimum standards and optimal targets for product development.

One of the key goals of the WHO profiles is to minimize the number of treatment encounters necessary for patients. For preventative TB treatment, the aim is to deliver a complete course with a single injection during one healthcare visit. For those with active TB, the target is to limit treatment duration to no more than four months, requiring three or fewer visits for dosing. These profiles emphasize the need for trained healthcare workers to administer injections at the lowest level of the health system, ensuring ease of delivery and no need for cold storage.

The development of these profiles involved extensive research and input from various stakeholders, including clinical trial experts, regulators, and individuals with personal experience of TB. While the potential of long-acting injectables is significant, the WHO stresses the importance of continuing research into improved oral treatments, ensuring that patient preferences are respected and that suitable options remain available for those who prefer not to receive injections. The profiles aim to facilitate the development of more convenient TB treatment regimens while prioritizing safety, effectiveness, and affordability.